Clinical Trials Logo

Vibrio Infections clinical trials

View clinical trials related to Vibrio Infections.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04451707 Completed - Vibrio Infections Clinical Trials

Epidemiology Non-cholera Vibrio Infections

INFECTIVE
Start date: March 12, 2020
Phase:
Study type: Observational

The purpose of this study is to identify the epidemiological and clinical characteristics of patients diagnosed with non-cholera Vibrio infection in Western France from 2000 to 2019.

NCT ID: NCT01233362 Completed - Cholera Clinical Trials

Study of Alternative Vaccination Schedule of Oral Cholera Vaccine

Start date: December 2010
Phase: Phase 2
Study type: Interventional

The absence of a boosting response after a 14 day interval with the two-dose regimen of the modified killed oral cholera vaccine raises the possibility that a longer dosing interval may be required to observe a boost in the immune response. This study will compare the immune responses following 14-day and 28-day dosing intervals.

NCT ID: NCT00741637 Completed - Diarrhea Clinical Trials

Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults

Start date: July 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and immunogenicity of Peru-15 (CholeraGarde®) vaccine in HIV seropositive adult population of Bangkok Thailand

NCT ID: NCT00419133 Completed - Diarrhea Clinical Trials

Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the safety and immunogenicity of one and two doses of the killed oral cholera vaccine.

NCT ID: NCT00289224 Completed - Diarrhea Clinical Trials

Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Start date: July 2006
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to estimate the efficacy of a two-dose regimen of the oral killed bivalent cholera vaccine when administered to individual residing in a cholera-endemic area in India.